MicroPort® Firehawk® Appears at the High-level Meeting on China-Africa Health Cooperation


Beijing, China – Recently, the High-level Meeting on China-Africa Health Cooperation, which was focused on "Intensifying China-Africa Health Cooperation, Jointly building a Silk Road of Health" and organized by National Health Commission of China, took place together with the 3rd Beijing Forum for Global Health and the 27th China International Medical Equipment Exhibition & Scientific Conference (China-Hospeq 2018) at the China National Convention Center in Beijing, China. The meeting featured in-depth discussions on the topics such as the building of disease control in Africa and China-Africa public health cooperation, the training of medical specialists, and innovation in China-Africa health cooperation models, so as to promote the matching of the policies of China and African countries.
On August 17 afternoon, a separate session organized by the Chinese Medical Doctor Association, namely the China-Africa Medical Talents Cultivation Symposium, was held. Representatives from the United Nations agencies, international non-government organizations, mainstream research institutes and nearly 100 medical experts from China and African countries were invited to the symposium. Professor Junbo Ge, who is an academician of the Chinese Academy of Sciences and head of Department of Cardiology of Zhongshan Hospital Affiliated to Fudan University, mentioned MicroPort® while introducing the Belt and Road cardiovascular intervention training program during the symposium. Early August, Professor Ge along with several other famous Chinese cardiologists and the Africa Aid Work Group of MicroPort® teamed up in a Chinese Africa Aid Goodwill Medical Mission to Republic of Ghana and provided short-term medical aids in the African country.
Professor Ge completed a PCI case with a Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). This case was assisted by Francis Agyekum, who is the first ever Chinese-trained Ghanaian surgeon capable of independently performing PCI procedure. Afterwards, MicroPort® donated a number of cardiovascular interventional products to Korle-Bu Teaching Hospital in the capital city of Accra to support the medical development in Ghana. The hospital is the biggest medical center in Ghana. The contribution by MicroPort® to the Belt and Road cardiovascular intervention training program was well received by the experts and scholars in attendance.
On August 18 afternoon, Lei Sun, head of Center for Medical Device Evaluation of China State Drug Administration, and others visited the MicroPort® booth during the concurrent 27th China International Medical Equipment Exhibition & Scientific Conference (China-Hospeq 2018). Sun paid special attention to the product features and clinical proofs of the world's third generation coronary drug-eluting stent of Firehawk® system, as well as the development, current business and diversified product lines of MicroPort® in details. Thus far, a total of 14 products of MicroPort® or its related companies have been granted entry into the special review and approval procedure for innovative medical devices ("the Green Path"). Mr. Sun said that it was not only a recognition of the independent innovation of MicroPort®, but would also expedite the marketing progress of the products and benefit more patients.
The MicroPort® products have entered the markets of over 10 countries included in China's Belt and Road Initiative, including India, Pakistan, Indonesia, the Philippines, Thailand, Kazakhstan, Malaysia, Poland, Romania, Korea and Turkey, continuously making positive contributions to the realization of a Silk Road for Health. The MicroPort® employees firmly believe that everyone is born with equal rights to medicine, health, and the pursuit of a longer life. Moreover, the MicroPort® employees will continue to deepen the bilateral healthcare cooperation with the pivotal countries included in the Belt and Road Initiative and devote themselves into a common destiny with the countries' patients and doctors, so as to actively create the revolutionary medical technologies to allow global citizens to enjoy the above rights. The vision of MicroPort® is that the people are the most essential aspect of building a leading, globalized medical corporation, where the patient always comes first, in the area of high-technology therapies embodied by minimally invasive and other emerging medical technologies. The mission of MicroPort® is that MicroPort® innovates relentlessly to commercialize the best, yet affordable, therapeutic solutions to save and reshape patients' lives, or to improve their quality of life. The centerpiece of the vision and mission of MicroPort® is to develop the highest-tech medical technologies in the world to bring health and longevity to every corner, community, family and patient of the world in the most fair and equitable way.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs MicroPort Scientific Corporation
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6957
Email: spokesperson@microport.com